Ambulance Services Market is Anticipated To Incur The Fastest Growth with a CAGR of 9.6% by 2028: Grand View Research Inc.

 

Ambulance Services Market Growth & Trends

The global ambulance services market size is expected to reach USD 67.7 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.6% from 2021 to 2028. Rising medical tourism and an increasing number of road accidents and CVD cases are the key driving factors for the market.

The growth of the market is due to favorable reimbursement policies in developed nations. In the U.S., Medicare covers both non-emergency and emergency ambulance services for medically necessary cases, if the supplier fulfills stipulated requirements. In some circumstances, Medicare also covers unscheduled and irregular non-emergency trips. Medicare covers 80.0% of the approved amount for emergency medical services and the remaining 20.0% is covered by the supplemental insurance policy of the patient. In New Jersey, Pennsylvania, and South Carolina, for repetitive, non-emergency trips, patients need prior authorization from Medicare Administrative Contractor (MAC). However, Medicare does not pay for ambulates (wheelchair-accessible vans that provide non-emergency transportation services).

In Victoria, Australia, patients can avail of emergency medical services by securing membership with Ambulance Victoria, which offers emergency medical services at subsidized prices. Ambulance Tasmania provides free emergency medical services to residents of Tasmania. Residents of Queensland (Australia) are covered with the cost of emergency services across Australia, by the QLD state government. Similarly, in the U.K., the public healthcare system provides free emergency and non-emergency medical services. In addition, patients receive NHS funding for their treatment. In Germany, public health insurance (Gesetzliche Krankenversicherung) is compulsory for every citizen and this insurance also covers non-emergency and emergency medical services. Private health insurance (Private Krankenversicherung) is usually opted by those who have high yearly income. Ease of payment through reimbursement policies encourages patients to opt for emergency medical services more frequently, which is likely to bolster the growth of the market.

Request a free sample copy or view report summary: Ambulance Services Market Report

Ambulance Services Market Report Highlights

• In terms of revenue, the ground ambulance segment held the largest share in 2020. The rising number of road accidents and increasing COVID-19 cases across the globe are major factors propelling segment growth
• The emergency services segment held the largest market share in 2020 and is expected to grow fast over the forecast period due to the increasing number of CVDs
• The Advanced Life Support (ALS) ambulance services segment held the largest market share in 2020. The growth of the segment is majorly driven by the increasing medical tourism across the globe
• In Asia Pacific, the market is expected to witness the fastest growth rate over the forecast period owing to the rising number of COVID-19 cases in the region

Access Press Release@ https://www.grandviewresearch.com/press-release/global-ambulance-services-market

Ambulance Services Market Segmentation

Grand View Research has segmented the global ambulance services market on the basis of transport vehicle, equipment, emergency services, and region:

Ambulance Services Transport Vehicle Outlook (Volume, Units; Revenue, USD Million, 2016 - 2028)

• Ground Ambulance
• Air Ambulance
• Water Ambulance

Ambulance Emergency Services Outlook (Volume, Units; Revenue, USD Million, 2016 - 2028)

• Emergency Services
• Non-emergency Services

Ambulance Services Equipment Outlook (Volume, Units; Revenue, USD Million, 2016 - 2028)

• Advanced Life Support (ALS) Ambulance Services
• Basic Life Support (BLS) Ambulance Services

Ambulance Services Regional Outlook (Volume, Units; Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa
  • South Africa
  • Saudi Arabia

List of Key Players of Ambulance Services Market

• Envision Healthcare
• London Ambulance Service NHS Trust
• Acadian Ambulance Service
• BVG India Limited
• America Ambulance Services, Inc.
• Falck Denmark A/S
• Air Medical Group Holdings, Inc. (AMGH)
• Air Methods Corporation
• Ziqitza Healthcare Limited
• Medivic Aviation

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

HPV Testing And Pap Test Market Size Likely To Reach $7.3 Billion By 2028: Grand View Research Inc.

 

HPV Testing And Pap Test Market Growth & Trends

The global HPV testing and Pap test market size is expected to reach USD 7.3 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 16.4% from 2021 to 2028. The introduction of innovative tests, increasing awareness programs, rising public-private investments, and high incidence of HPV infections are some of the factors anticipated to foster market growth during the forecast period.

Cervical cancer is a global problem, affecting millions of women. As per the Globocan estimates, in 2020, around 604,127 new cases of the cervix and uterine cancer were diagnosed globally, which led to around 341,831 deaths in the same year. According to the WHO, 99% of cervical cancer cases are linked with HPV infection. Such a high incidence and mortality rate of the disease has created a major demand for innovative and accurate screening for early detection and management. In addition, approval of novel testing solutions and services to upsurge screening rates is further anticipated to support market growth. In April 2020, Roche received FDA approval for its cobas HPV screening to be used on cobas 6800/8800 Systems, a fully automated and high-throughput system. Also, in February 2019, the Japanese company CMIC Healthcare Co., Ltd. launched SelCheck Cervical Cancer, a self-collect HPV test service focused on increasing the frequency of screening rates in the country.

The outbreak of novel coronavirus (COVID-19) and nationwide lockdowns due to it in key geographies has drastically reduced the routine cervical cancer screening procedures. According to data published by the CDC, due to stay-at-home orders, the cervical cancer screening rate decreased by around 80% in California, U.S. Thus, such decreased testing rates have negatively affected the overall revenue growth of the market in 2020. However, increasing government initiatives to control the reducing testing rates is anticipated to offset the impact of COVID-19 in the near future. For instance, in February 2021, NHS England initiated a trial and offered at-home HPV testing kits to more than 31,000 women to carry out screening in the privacy and convenience of their own homes. This trial aims to increase the HPV screening rate in the country.

Request a free sample copy or view report summary: HPV Testing And Pap Test Market Report

HPV Testing And Pap Test Market Report Highlights

• Based on test type, the Pap test segment accounted for the largest revenue share in 2020, owing to its widespread use in cervical cancer screening programs
• By application, the cervical cancer screening segment dominated the market in 2020, due to its higher incidence and mortality rates
• By product type, the consumables segment dominated the market in 2020, owing to its repetitive use to conduct testing in hospitals and laboratories
• The PCR segment is projected to show the fastest growth rate in the technology segment, owing to the enactment of new recommendations to use DNA HPV testing
• In Asia Pacific, the market is expected to witness lucrative growth as a result of the growing demand for HPV and Pap tests from emerging economies, such as China and India, which have a huge target population

Access Press Release@ https://www.grandviewresearch.com/press-release/global-hpv-test-pap-test-market

HPV Testing And Pap Test Market Segmentation

Grand View Research has segmented the global HPV testing and Pap test market on the basis of test type, application, product, technology, end-use, and region:

HPV Testing & Pap Test Type Outlook (Revenue, USD Million, 2016 - 2028)

• HPV Testing
• Pap Test

HPV Testing & Pap Test Application Outlook (Revenue, USD Million, 2016 - 2028)

• Cervical Cancer Screening
• Vaginal Cancer Screening

HPV Testing & Pap Test Product Outlook (Revenue, USD Million, 2016 - 2028)

• Instruments
• Consumables
• Services

HPV Testing & Pap Test Technology Outlook (Revenue, USD Million, 2016 - 2028)

• PCR
• Immunodiagnostics
• Other Technologies

HPV Testing & Pap Test End-use Outlook (Revenue, USD Million, 2016 - 2028)

• Hospitals & Clinics
• Laboratories
• Others

HPV Testing & Pap Test Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Italy
  • Spain
  • Russia
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Singapore
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE

List of Key Players of HPV Testing And Pap Test Market

• Abbott Laboratories
• Qiagen N.V.
• Becton, Dickinson and Company
• Quest Diagnostics, Inc.
• Hologic, Inc.
• Hoffmann-La Roche
• Femasys, Inc.
• Arbor Vita Corporation
• NURX, Inc.
• Seegene, Inc.
• Thermo Fisher Scientific, Inc.
• bioMérieux SA

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

𝐓𝐞𝐥𝐞𝐜𝐨𝐦 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬: 𝐁𝐫𝐨𝐚𝐝𝐛𝐚𝐧𝐝 𝐁𝐨𝐨𝐦

 

𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞- https://www.grandviewresearch.com/industry-analysis/global-telecom-services-market

Rising spending on the deployment of 5G infrastructures due to the shift in customer inclination toward next-generation technologies and smartphone devices is one of the key factors driving this industry. An increasing number of mobile subscribers, soaring demand for high-speed data connectivity, and the growing demand for value-added managed services are the other potential factors fueling the market growth. The global communication network has undoubtedly been one of the prominent areas for continued technological advancements over the past few decades.

𝐁𝐥𝐨𝐜𝐤𝐜𝐡𝐚𝐢𝐧 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 : 𝐓𝐡𝐞 𝐁𝐞𝐠𝐢𝐧𝐧𝐢𝐧𝐠 𝐨𝐟 𝐚 𝐍𝐞𝐰 𝐄𝐫𝐚 𝐢𝐧 𝐓𝐫𝐚𝐜𝐞𝐚𝐛𝐢𝐥𝐢𝐭𝐲

 

Know More@ https://www.grandviewresearch.com/industry-analysis/blockchain-technology-market

Blockchain has emerged as a highly promising technology in the IT domain. It is an open, immutable, distributed public ledger that can be accessed by several parties involved in the transaction and acts as a universal depository of all transactions between the involved parties. The increasing acceptance of cryptocurrency worldwide is one of the major factors driving market growth. Commercial and central banks across the world are now using blockchain technology for payment processing and issuing of their digital currencies. The technology enables cross-border payments that are less expensive and faster as compared to traditional systems.

Clinical Trials Market Size Is Expected To Reach USD 69.3 Billion by 2028

 Clinical Trials Market Growth & Trends

The global clinical trials market size is expected to reach USD 69.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.7% from 2021 to 2028. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and other products. The market witnessed a decline of 6.0% in 2020 owing to the COVID-19 pandemic. However, the market is projected to recover from 2021 onwards. Also, clinical trials have become increasingly costly ventures, adding to the overall cost of developing a drug. Hence, big pharmaceuticals and small biotechnology firms are looking for innovative ways to improve trial outcomes and decrease operational costs.

The increasing need to develop new therapeutics for chronic diseases such as cancer, respiratory disorder, diabetes, cardiovascular disease, and others is creating immense pressure on healthcare. The global pandemic caused due to COVID-19 and the increasing demand for developing a suitable treatment for the same is driving the market’s growth. The number of people affected by the coronavirus has reached one million, which further depicts an increasing need for therapeutics and vaccines. Currently, there are 288therapeutics and 106 vaccines in development. Out of this, nearly 7.0% of therapeutics are in Phase IV, 21.0% in Phase III, and 43.0% and 13.0% in Phase II and Phase I respectively.

The pandemic has also resulted in the global disruption of traditional onsite clinical trials. Hence, regulatory bodies all over the world have launched various initiatives for fast-tracking clinical trials for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the WHO to find effective treatment against COVID-19.

Though COVID-19 is forcing many medical device and drug developers to revise the approach they prepare for these types of crises, integrating best practices within clinical trial procedures and adapting to virtual trials can support the continuous development of therapeutics even in the presence of this pandemic.

Request a free sample copy or view report summary: Clinical Trials Market Report

Clinical Trials Market Report Highlights

• The phase III segment dominated the market and accounted for the largest revenue share of 53.2% in 2020. This is attributed to the complexity level associated with this phase
• The interventional segment accounted for the largest revenue share of 82.1% in 2020 owing to the increasing demand for the intervention for clinical trials by researchers
• North America dominated the market and accounted for the largest revenue share of 51.0% in 2020. Favorable government initiatives and the presence of large numbers of players in the U.S. offerings advanced services are responsible for market growth
• In Asia Pacific, the market is expected to expand at the fastest CAGR of 6.7% over the forecast period owing to the increasing patient pool and cost-efficient services

Access Press Release@ https://www.grandviewresearch.com/press-release/clinical-trials-market

Clinical Trials Market Segmentation

Grand View Research has segmented the global clinical trials market based on phase, study design, indication, indication by study design, and region:

Clinical Trials Phase Outlook (Revenue, USD Million, 2016 - 2028)

• Phase I
• Phase II
• Phase III
• Phase IV

Clinical Trials Study Design Outlook (Revenue, USD Million, 2016 - 2028)

• Interventional
• Observational
• Expanded Access

Clinical Trials Indication Outlook (Revenue, USD Million, 2016 - 2028)

• Autoimmune/Inflammation
  • Rheumatoid arthritis
  • Multiple sclerosis
  • Osteoarthritis
  • Irritable Bowel Syndrome (IBS)
  • Others
• Pain management
  • Chronic pain
  • Acute pain
• Oncology
  • Blood cancer
  • Solid tumors
  • Other
• CNS condition
  • Epilepsy
  • Parkinson's Disease (PD)
  • Huntington's Disease
  • Stroke
  • Traumatic Brain Injury (TBI)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Muscle regeneration
  • Others
• Diabetes
• Obesity
• Cardiovascular
• Others

Clinical Trials Indication By Study Design Outlook (Revenue, USD Million, 2016 - 2028)

• Autoimmune/Inflammation
  • Interventional
  • Observational
  • Expanded Access
• Pain management
  • Interventional
  • Observational
  • Expanded Access
• Oncology
  • Interventional
  • Observational
  • Expanded Access
• CNS condition
  • Interventional
  • Observational
  • Expanded Access
• Diabetes
  • Interventional
  • Observational
  • Expanded Access
• Obesity
  • Interventional
  • Observational
  • Expanded Access
• Cardiovascular
  • Interventional
  • Observational
  • Expanded Access
• Others
  • Interventional
  • Observational
  • Expanded Access

Clinical Trials Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Spain
  • Italy
• Asia Pacific
  • India
  • Japan
  • China
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

List of Key Players of Clinical Trials Market

• ICON Plc
• Wuxi AppTec
• PRA Health Sciences
• SGS SA
• Syneos Health
• Eli Lilly and Company
• Novo Nordisk A/S
• Pfizer
• Clinipace

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Continuous Glucose Monitoring Device Market Industry Analysis , Opportunity Assessment And Forecast Till 2028: Grand View Research Inc.

 Continuous Glucose Monitoring Device Market Growth & Trends

The global continuous glucose monitoring device market size is expected to reach USD 10.36 billion by 2028, according to a new study by Grand View Research, Inc. It is expected to expand at a CAGR of 10.1% from 2021 to 2028. Growing cases of diabetes and introduction of novel and advanced diabetes care devices are the major factors driving the market growth. Continuous glucose monitoring (CGM) devices provide an efficient method to measure body glucose levels in real time. Data recorded by these devices is transmitted through a wireless network to receivers; this helps keep a track of glucose levels over a designated period.

These devices also help manage diabetes while reducing individual insulin dosages. Integrated software within these devices provides users with insights about food consumption, medication, physical activity, and illnesses. Thus, an increasing number of diabetic patients are using these devices to manage and treat diabetes, which, in turn, is accelerating market growth. With the advent of digital therapeutics, a rising number of continuous glucose monitoring devices are being incorporated with apps and software to help patients with diabetes mellitus. Rise in the number of diabetes mellitus has been contributing toward continuous glucose monitoring (CGM) systems market growth.

Request a free sample copy or view report summary: Continuous Glucose Monitoring Device Market Report

Continuous Glucose Monitoring Device Market Report Highlights

• Growing cases of diabetes is anticipated to propel market growth, with increasing number of patients opting for simplified CGM devices
• CGM devices provide analysis of blood glucose levels from the tissue fluid at regular intervals of time, which is also driving their demand
• Sensors was the largest component type segment and is anticipated to maintain its dominance owing to their integral nature in these devices
• Asia Pacific is the leading regional continuous glucose monitoring device market, with Japan, China, and India on the forefront
• North America led the global market in the past owing to wide usage of CGM devices as a result of higher number of target patients in the region
• The European region followed the North American closely in terms of market revenue due to rise in the adoption of these devices in key countries such as U.K., Germany, France, Italy, and Spain
• Some of the key companies present in the market are Pfizer Inc.; Baxter International, Inc.; Abbott Laboratories; Medtronic PLC; Animas Corporation; and Novo Nordisk A/S.

Access Press Release@ https://www.grandviewresearch.com/press-release/global-continuous-glucose-monitoring-cgm-devices-market

Continuous Glucose Monitoring Device Market Segmentation

Grand View Research has segmented the global continuous glucose monitoring device market on the basis of component, end use, and region:

CGM Devices Component Outlook (Revenue, USD Million, 2016 - 2028)

• Transmitters
• Sensors
• Receivers

CGM Devices End-use Outlook (Revenue, USD Million, 2016 - 2028)

• Hospitals
• Home Care
• Others

CGM Devices Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
• Asia Pacific
  • China
  • India
• Latin America
  • Brazil
  • Mexico
• MEA
  • South Africa
  • Saudi Arabia

List of Key Players of Continuous Glucose Monitoring Device Market

• Medtronic
• Dexcom, Inc.
• Hoffmann-La Roche Ltd.
• Abbott
• Novo Nordisk A/S
• Ypsomed
• GlySens, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Facial Injectable Market Trends Regulations And Competitive Landscape Outlook to 2028

 Facial Injectable Market Growth & Trends

The global facial injectable market size is expected to reach USD 27.7 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.8% from 2021 to 2028. The facial injectable is a substance that is used to reduce wrinkles and restore volume and fullness in the face. It is injected beneath the facial skin surface. Some commonly used facial injectables include hyaluronic acid, botulinum toxin type A, and polymer fillers.

The growing focus on physical appearance, especially in developing countries, is one of the key factors expected to drive the market. In addition, a shift in consumer preference toward minimally invasive procedures is expected to support market growth. According to the American Society of Plastic Surgeons (ASPS), in 2019, botulinum toxin A and soft tissue fillers were among the top 5 minimally invasive procedures carried out in the U.S. Thus, facial injectable holds high growth prospects in the years to come.

The Asia Pacific region is expected to serve as a key revenue-generating center. The region is backed by countries, such as India, where a growing focus on physical appearance is expected to create a lucrative opportunity for the market. Companies such as Allergan are also expanding their presence in the country owing to the rise in the middle-class population, backed by increasing disposable income.

With non-urgent and cosmetic surgeries being put on hold in most of the clinics across the world, surgeons are consulting their patients via telemedicine. Some surgeons are expecting an initial rush once the clinic reopens due to backlog cases, however, in the long run, they predict changes in the near future. There will also be an additional impact on revenue. With deep sanitization and PPEs to be worn for even injectable procedures, small businesses are expected to undergo the overhead expense and a decreased revenue, many could even shut down.

Request a free sample copy or view report summary: Facial Injectable Market Report

Facial Injectable Market Report Highlights

• By product, the botulinum toxin type A segment led the market in 2020 and is projected to dominate throughout the forecast period. It is one of the most popularly used minimally invasive procedures
• Based on application, the aesthetics segment is projected to be the fastest-growing segment over the forecast period owing to the rise in the use of facial injectables for aesthetic procedures, such as the treatment of wrinkles on the face
• North America dominated the market in 2020 with a share of over 41.0% owing to the easy availability of the products and the presence of a large number of skilled surgeons

Access Press Release@ https://www.grandviewresearch.com/press-release/global-facial-injectables-market

Facial Injectable Market Segmentation

Grand View Research has segmented the global facial injectable market on the basis of product, application, and region:

Facial Injectable Product Outlook (Volume, Number of Procedures, USD Million, 2016 - 2028)

• Collagen
• Hyaluronic Acid (HA)
• Botulinum Toxin Type A
• Calcium Hydroxylapatite (CaHA)
• Polymer Fillers
  • Polymethylmethacrylate beads (PMMA Microspheres)
  • Poly-L-Lactic Acid (PLLA)

Facial Injectable Application Outlook (Revenue, USD Million, 2016 - 2028)

• Aesthetics
• Therapeutics 

Facial Injectable Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
  • Switzerland
  • Netherland
  • Belgium
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
  • Malaysia
  • Singapore
  • Indonesia
  • Philippines
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey

List of Key Players of Facial Injectable Market

• Allergan
• Hologic (cynosure)
• Johnson & Johnson
• Galderma
• Lumenis
• Solta Medical
• Syneron Candela
• Alma Laser

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Biobanks Market Will Target Emerging Markets By 2028

 Biobanks Market Growth & Trends

The global biobanks market size is expected to reach USD 106.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.2% from 2021 to 2028. Biobanks continue to evolve with the introduction of new technologies such as NGS and increased focus on genomic medicine. The availability of several types of biospecimens to cater to multiple domains including drug discovery, diagnostics, and others has accelerated the diversification of biorepositories, thereby driving the market.

The quality of biospecimens can significantly influence the disease testing as well as preclinical and clinical research. Regulatory agencies have played a vital role in spurring the adoption of biobanking services by establishing guidelines for the effective management of samples. For instance, the U.S. Centers for Disease Control and Prevention (CDC) released guidelines to minimize human hazards while handling COVID-19 samples.

This serves as a model for other biorepositories. Furthermore, as the number of research studies and clinical trials related to COVID-19 is increasing, the demand for high-quality biospecimens is expected to significantly increase in the near future, leading to market growth. In addition, population-based cohort studies are facilitated by biorepositories to estimate the actual seroprevalence. Health Catalyst, Inc., through its Touchstone platform, provides national data related to COVID-19 insights. Such factors are anticipated to contribute to the revenue flow in this space.

Request a free sample copy or view report summary: Biobanks Market Report

Biobanks Market Report Highlights

• The biobanking equipment segment accounted for the maximum revenue share in 2020 owing to the high cost of instruments coupled with an increase in the number of biorepositories
• The biobanking and repository services segment accounted for the largest revenue share of 36.0% in the market
• This is because of the higher penetration of these services and the increased need for the preservation of biosamples for developing precision medicineand disease-specific research
• Human tissues are the most stored sample for clinical research, resulting in the dominance of this sample type in the market
• The virtual biobanks segment is anticipated to witness the fastest growth rate over the forecast period owing to the growing demand for 3D biospecimens coupled with the need for rare disease data for biomedical research
• The therapeutics application segment accounted for the largest revenue share in 2020 owing to the growing popularity of cell therapies for cancer treatment
• Several pharma/biotech companies have established their private banks to support clinical trials and the development of cell therapies, resulting in revenue growth in this segment
• North America dominated the market with its wide network of centers for biosample storage in the U.S.
• Moreover, a high number of COVID-19 cases in the U.S. and increased R&D programs have resulted in the establishment of new biorepositories, thereby driving the revenue in North America
• In Asia Pacific, the market is anticipated to register the fastest growth owing to the ever-expanding pharmaceuticals and clinical research domain across the Asian countries
• The key players are engaged in expanding their global reach by partnering with global distributors, merger, and acquisition of other players, and entering a strategic alliance with research communities

Access Press Release@ https://www.grandviewresearch.com/press-release/global-biobanks-industry

Biobanks Market Segmentation

Grand View Research has segmented the global biobanks market on the basis of product, service, biospecimen type, biobanks type, application, and region:

Biobanks Product Outlook (Revenue, USD Million, 2017 - 2028)

• Biobanking Equipment
  • Temperature Control Systems
    • Freezers & Refrigerators
    • Cryogenic Storage Systems
    • Thawing Equipment
  • Incubators & Centrifuges
  • Alarms & Monitoring Systems
  • Accessories & Other Equipment
• Biobanking Consumables
• Laboratory Information Management Systems

Biobanks Service Outlook (Revenue, USD Million, 2017 - 2028)

• Biobanking & Repository
• Lab processing
• Qualification/ Validation
• Cold Chain Logistics
• Other Services

Biobanks Biospecimen Type Outlook (Revenue, USD Million, 2017 - 2028)

• Human Tissues
• Organs
• Stem Cells
  • Adult Stem Cells
  • Embryonic Stem Cells
  • IPS Cells
  • Other Stem Cells
• Other Biospecimens

Biobanks Type Outlook (Revenue, USD Million, 2017 - 2028)

• Physical/Real Biobanks
  • Tissue Biobanks
  • Population Based Biobanks
  • Genetic (DNA/RNA)
  • Disease Based Biobanks
• Virtual Biobanks

Biobanks Application Outlook (Revenue, USD Million, 2017 - 2028)

• Therapeutics
• Drug Discovery & Clinical Research
• Clinical Diagnostics
• Other Applications

Biobanks Regional Outlook (Revenue, USD Million, 2017 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Spain
  • Italy
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Singapore
• Latin America
  • Brazil
• Middle East & Africa
  • South Africa

List of Key Players of Biobanks Market

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• QIAGEN
• Hamilton Company
• Avantor
• Tecan Trading AG.
• Danaher Corporation
• Becton, Dickinson and Company (BD)
• BioCision
• Taylor-Wharton
• Charles River Laboratories
• Lonza
• STEMCELL Technologies Inc.
• Biovault Family
• PromoCell GmbH
• Precision Cellular Storage Ltd. (Virgin Health Bank)

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Healthcare IT Market is Anticipated To Reach $166.0 Billion by 2028: Grand View Research Inc.

 

Healthcare IT Market Growth & Trends

The global healthcare IT market size is expected to reach USD 166.0 billion by 2028 and is expected to grow at a CAGR of 10.7% over the forecast period, according to a new report by Grand View Research, Inc. Rising demand and adoption of preventive care along with increasing funding for various mobile health startups is boosting the market growth. In addition, growing network coverage and rising improvements in network infrastructure are further driving the market.

The Covid-19 pandemic has also boosted the demand for online or virtual medical consultancy, globally, owing to the developments and innovations in internet-based technologies, the growing prevalence of chronic diseases, and increasing adoption and positive consumer behavior pertaining to newer technologies in healthcare. According to a 2020 survey conducted by Deloitte, the pandemic propelled the adoption of virtual health. For instance, the percent of consumers or respondents utilizing virtual visits increased from 15% in 2019 to 19% in the initial months of 2020 and a sudden spike of around 28% was witnessed in April 2020. Thus, such instances are likely to support market growth in the coming years.

In 2020, the Electronic Health Records (EHRs) application segment dominated the global market accounting for a revenue share of over 40%. This growth was attributed to the surge in demand for streamlining EHR, EHR-integrated tools, and advancements in information technology. Furthermore, the segment is estimated to retain its leading position throughout the forecast years due to factors, such as growing awareness and adoption in healthcare facilities, strategic initiatives by key players in the healthcare IT space, and an increasing number of initiatives supporting its implementation. For instance, in 2020, Cerner announced the launch of its first virtual EHR implementation in Macon Community Hospital, Tennessee.

Request a free sample copy or view report summary: Healthcare IT Market Report

Healthcare IT Market Report Highlights

• The market is anticipated to witness significant growth over the forecast period owing to the rising demand and adoption of preventive care
• North America dominated the global market in 2020 and will grow further at a steady CAGR from 2021 to 2028
• This growth is credited to the rising adoption and implementation of IT services and solutions by healthcare providers for delivering enhanced patient care at lower expenses
• Moreover, the increasing number of hospitals, advanced research centers, and universities along with the presence of key manufacturing hubs in North America will support the market growth in the region

Access Press Release@ https://www.grandviewresearch.com/press-release/global-healthcare-it-market

Healthcare IT Market Segmentation

Grand View Research has segmented the global healthcare IT market on the basis of application and region:

Healthcare IT Application Outlook (Revenue, USD Million, 2016 - 2028)

• Electronic Health Records (EHRs)
• Computerized Provider Order Entry Systems (CPOE)
• Electronic Prescribing Systems
• PACS
• Laboratory Information Systems
• Clinical Information Systems
• Tele-healthcare

Healthcare IT Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Singapore
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa
  • South Africa
  • Saudi Arabia

List of Key Players of Healthcare IT Market

• Philips Healthcare
• Agfa Healthcare
• Hewlett-Packard Enterprise
• Carestream Health
• GE Healthcare
• E-MDS, Inc.
• Athenahealth, Inc.
• eClinicalworks
• McKesson Corporation

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

The Next Wave: Virtual Reality Headsets

 

Know More@ https://www.grandviewresearch.com/industry-analysis/virtual-reality-vr-headset-market

VR technology has a vast potential to be used in a broad range of applications, such as medical training, industrial prototyping, and education. The rising investments in this technology by enterprises as well as consumers are expected to boost the product demand over the forecast period. The emerging trends in VR technology have an immediate impact on the developments in the VR headset industry, such as the introduction of convenient, attractive, and sleek VR headsets.

Pharmacovigilance Market Expectations Acme Prominent Development in Developed Regions, Details Gvr Study

 Pharmacovigilance Market Growth & Trends

The global pharmacovigilance market size is expected to reach USD 14.95 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 11.5% from 2021 to 2028. The increasing incidence of Adverse Drug Reactions (ADR) is the key growth factor. ADR imposes a substantial burden on healthcare systems and is one of the prominent causes of morbidity in developed countries. According to the National Center for Biotechnology Information (NCBI), approximately 5% of total hospitalizations in Europe each year are due to ADR. Pharmacovigilance services play an integral role in this clinical trial phase by assisting manufacturers in identifying adverse effects associated with the drug.

According to the World Health Organization's (WHO) report on pharmaceutical consumption, medicines to treat chronic diseases accounted for a larger proportion of the total volume of drug consumption in non-hospital setups. Hence, there has been a significant rise in the number of medicines made available to healthcare consumers. The rising demand for drugs has significantly heightened the need for the development of novel therapeutics via extensive clinical trials, which is expected to serve this market with lucrative opportunities.

Moreover, leading pharma companies in developed countries are focusing on outsourcing PV services to reduce costs and minimize operational expenses. This is anticipated to serve as an opportunity for contact research organizations in developing regions to gain more revenue share. Manufacturers are now focusing on remodeling their product development processes in an attempt to cater to patient needs across the globe. These factors are anticipated to fuel the demand for pharmacovigilance services during the forecast period.

Industry participants are focusing on increasing R&D activities to develop better pharmacovigilance services. Companies are also adopting strategies including new product launches and mergers & acquisitions to gain a competitive advantage. Moreover, they are undertaking collaborations with the PV service providers to gain access to medical information and manage PV workflows. For instance, in September 2019, Accenture collaborated with Bayer to implement the company's INTIENT Clinical platform to simplify and speed up its drug development processes, thereby widening its business. The company collaborated with BioCelebrate in 2017 to develop a platform for aggregating and analyzing clinical information for improved drug development efficiency, thus enhancing its R&D capabilities. Such initiatives help companies maintain their market position.

Request a free sample copy or view report summary: Pharmacovigilance Market Report

Pharmacovigilance Market Report Highlights

• By product life cycle, phase IV held a dominant share of 75.61% in 2020 owing to the extensive post-marketing surveillance of pharmaceuticals and an increasing number of ADR incidences in the market
• In terms of service provider, contract outsourcing held a significant share of 59.24% as of 2020 owing to the shift in the focus of pharmaceutical companies to outsourcing services to reduce operational cost
• Based on type, spontaneous reporting held the largest revenue share in 2020 due to its wide application in pharmacovigilance and benefits such as easy simulation of data sets for better drug comparison
• On the basis of end-use, the biotechnology companies segment is anticipated to exhibit a lucrative CAGR of 12.6% over the forecast period owing to the increasing R&D for the development of novel biologics
• Asia Pacific is anticipated to exhibit a lucrative CAGR of 13.2% in the forthcoming years. This is attributed to the availability of low-cost labor and the rising number of outsourcing companies in this region

Access Press Release@ https://www.grandviewresearch.com/press-release/global-pharmacovigilance-market

Pharmacovigilance Market Segmentation

Grand View Research has segmented the global pharmacovigilance market on the basis of the service provider, product life cycle, type, process flow, therapeutic area, end-use, and region:

Pharmacovigilance Service Provider Outlook (Revenue, USD Million, 2016 - 2028)

• In-house
• Contract Outsourcing

Pharmacovigilance Product Life Cycle Outlook (Revenue, USD Million, 2016 - 2028)

• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV

Pharmacovigilance Type Outlook (Revenue, USD Million, 2016 - 2028)

• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

Pharmacovigilance Process Flow Outlook (Revenue, USD Million, 2016 - 2028)

• Case Data Management
  • Case Logging
  • Case Data Analysis
  • Medical Reviewing & Reporting
• Signal Detection
  • Adverse Event Logging
  • Adverse Event Analysis
  • Adverse Event Review & Reporting
• Risk Management System
  • Risk Evaluation System
  • Risk Mitigation System

Pharmacovigilance Therapeutic Area Outlook (Revenue, USD Million, 2016 - 2028)

• Oncology
• Neurology
• Cardiology
• Respiratory Systems
• Others

Pharmacovigilance End-use Outlook (Revenue, USD Million, 2016 - 2028)

• Pharmaceuticals
• Biotechnology Companies
• Medical Device Manufacturers
• Others

Pharmacovigilance Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia Pacific
  • Japan
  • China
  • India
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • South Africa
  • Kingdom of Saudi Arabia

List of Key Players of Pharmacovigilance Market

• Accenture
• Linical Accelovance
• IQVIA
• Cognizant
• Laboratory Corporation of America Holdings
• IBM Corporation
• ArisGlobal
• ICON Plc.
• Capgemini
• ITClinical
• TAKE Solutions
• PAREXEL International Corporation
• BioClinica, Inc.
• Wipro Limited
• UNITED BIOSOURCE CORPORATION
• FMD K&L

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Point Of Care Diagnostics & Testing Market Poised to Expand at a Robust Pace of USD 35.74 Billion Over 2028: Grand View Research Inc.

 Point Of Care Diagnostics & Testing Market Growth & Trends

The global point of care diagnostics & testing market size is estimated to reach USD 35.74 billion by 2028, registering a CAGR of 3.25%, according to a new report by Grand View Research, Inc. Point of care (POC) diagnostics & testing has significantly altered the therapeutic models applied for the treatment of diabetic patients, HIV patients, and patients with Cardiovascular Disorders (CVDs), in recent years. In addition, emerging advancements on the horizon are projected to enhance the near-patient treatment workflows for infectious diseases, strokes, and cancer.

The industry is set to witness lucrative growth as POC testing serves as a profitable alternative to traditional laboratory tests. Point-of-care devices are designed to offer actionable information at the location and time of patient care, which enables early diagnosis of diseases. The advent of non-invasive & minimally invasive POC devices, continuous POCT, miniaturized technologies, and the adoption of telemedicine in remote patient monitoring are some of the key trends contributing to the market growth.

Moreover, the advent of rapid data sharing solutions as well as platforms is set to contribute to the development of POC COVID-19 tests, supplementing the overall market growth. Companies actively working toward the development of such rapid data sharing solutions include Foundation for Innovative New Diagnostics (FIND) and 360 Dx. The rising number of such companies is set to offer manufacturers/developers and professionals a clear perspective with respect to the future opportunities associated with POC COVID-19 tests.

The development of multiplex POC diagnostic technologies that enable the detection of multiple infectious pathogens in specimens, such as sputum, urine, or blood, offers improved patient outcomes and better disease diagnosis. The wide adoption of multiplex POC devices is anticipated to serve as a driver for the shift in preference from a centralized disease testing model to a decentralized patient-centered model.

Major companies are initiating strategic product launches to strengthen their market presence. For instance, in October 2020, Roche announced the launch of the Elecsys SARS-CoV-2 Antigen test that supports COVID-19 testing of suspected patients at high volumes. In April 2020, Nova Biomedical introduced PT/INR testing for its Allegro capillary blood analyzer to be used in POC primary care settings. This test is available in CE-regulated countries.

PR/INR is among the total 18 tests of the Allegro platform and is designed to measure HbA1c, hemoglobin, cholesterol, glucose, triglycerides, UACR, creatinine, hematocrit, and uric acid. This product expanded the testing portfolio of the company’s Allergo platform.

Request a free sample copy or view report summary: Point Of Care Diagnostics & Testing Market Report

Point of Care Diagnostics & Testing Market Report Highlights

• The glucose testing product segment led the market in 2020 due to high demand for POC glucose monitors for routine glucose testing as a result of an increased number of diabetic patients across the globe
• The infectious disease product segment is expected to account for the highest revenue share by 2028. This growth is majorly attributed to the global COVID-19 pandemic
• The first POC diagnostic test for COVID-19 was approved by the U.S. FDA in March 2020 under Emergency Use Authorization, which was manufactured by Cepheid
• Since then, key players in this market are engaged in developing and manufacturing such tests, which, in turn, is boosting the segment growth
• The clinics end-use segment accounted for the dominant revenue share in 2020 and will expand further at a steady CAGR from 2021 to 2028 owing to increasing transition from conventional lab testing to POCT by healthcare professionals to shorten the time taken for diagnosis and further treatments
• Led by the U.S., North America was the leading regional market in 2020 and held a revenue share of more than 34%

Access Press Release@ https://www.grandviewresearch.com/press-release/global-point-of-care-diagnostics-market

Point Of Care Diagnostics & Testing Market Segmentation

Grand View Research has segmented the global point of care diagnostics & testing market on the basis of product, end-use, and region:

POC Diagnostics & Testing Product Outlook (Revenue, USD Million, 2017 - 2028)

• Glucose Testing
• Hb1Ac Testing
• Coagulation
• Fertility
• Infectious Diseases
  • HIV
  • Clostridium Difficile
  • HBV
  • Pneumonia or Streptococcus Associated Infections
  • Respiratory Syncytial Virus (RSV)
  • HPV
  • Influenza/Flu
  • HCV
  • MRSA
  • TB and Drug-Resistant TB
  • HSV
  • COVID-19
  • Other Infectious Diseases
• Cardiac Markers
• Thyroid Stimulating Hormone
• Hematology
• Primary Care Systems
• Decentralized Clinical Chemistry
• Feces
• Lipid Testing
• Cancer Marker
• Blood Gas/Electrolytes
• Ambulatory Chemistry
• Drug Abuse Testing
• Urinalysis

POC Diagnostics & Testing End-use Outlook (Revenue, USD Million, 2017 - 2028)

• Clinics
  • Pharmacy & Retail Clinics
  • Physician Office
  • Urgent Care Clinics
  • Non-practice Clinics
• Hospitals
• Home
• Assisted Living Healthcare Facilities
• Laboratory

POC Diagnostics & Testing Regional Outlook (Revenue, USD Million, 2017 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Italy
  • Spain
  • Russia
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Korea
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa (MEA)
  • South Africa
  • Saudi Arabia

List of Key Players of POC Diagnostics & Testing Market

• Hoffmann-La Roche Ltd.
• Qiagen
• Danaher Corp.
• Becton Dickinson (BD)
• Biomerieux SA
• Abbott Laboratories
• Siemens Healthcare AG
• Zoetis, Inc.
• Instrumentation Laboratory
• Nova Biomedical
• Trividia Health, Inc.
• Quidel Corp.
• Trinity Biotech
• Sekisui Diagnostics
• Orasure Technologies, Inc.
• Nipro Corp.
• Spectral Medical, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.